1. Introduction {#sec1}
===============

Glaucoma is the second leading cause of blindness, affecting approximately 60.5 million people worldwide or about 2.6% of the population over the age of 40 \[[@B1]\]. Although the most prevalent form of glaucoma in western countries and in many other parts of the world is open-angle glaucoma (OAG) \[[@B1]\], angle-closure glaucoma (ACG) is the most common type of glaucoma among the Han Chinese \[[@B2]\].

Blindness due to glaucoma may be preventable if patients are given adequate treatment. Factors associated with the development of glaucoma include increased intraocular pressure (IOP), higher cup-to-disc ratio, aging, thinner central corneal thickness, family history of glaucoma, myopia, and chronic and systemic diseases such as diabetes \[[@B3], [@B4]\]. Most ophthalmologists treat glaucoma by lowering the IOP using one of three modalities---topical antiglaucoma drugs, laser treatment, or glaucoma surgery. Types of topical medication include *β*-blockers, *α*-agonists, prostaglandin analogs (PAGs), carbonic anhydrase inhibitors (CAIs), cholinergic agonists, and adrenergic agonists \[[@B5]\]. Because some patients require multiple daily dosing, fixed combination eye drops have been developed to enhance and reinforce patient compliance \[[@B6]\].

Recent studies have shown that glaucoma treatment in some developed countries causes a significant financial burden on the health care system \[[@B7]--[@B9]\]. In this study, we used the National Longitudinal Health Insurance Database 2000 (LHID2000) to examine trends in glaucoma medication expenditure in Taiwan from 1997 to 2010. The Taiwan National Health Insurance (NHI) program is a mandatory single-payer health insurance system under which all residents are covered. The NHI program has been in existence since 1995 and by the end of 2010 the coverage rate was 99% of Taiwan\'s population of 23.1 million. Health spending accounted for 6.9% of GDP in Taiwan. Medical care in Taiwan is well known for its low cost, convenience, high efficiency, high quality, and excellent medical accessibility \[[@B10]--[@B12]\]. The nationwide population-based dataset provides an opportunity to explore the trends in glaucoma medication expenditure.

2. Materials and Methods {#sec2}
========================

2.1. Database {#sec2.1}
-------------

This study was designed as a population-wide retrospective review using the Taiwan National Health Insurance Research Database (NHIRD). The NHIRD contains a large number of computerized records including registration files, medication and treatment regimens, and information on surgery. Claim reimbursement data from patients since 1999 are provided to researchers in an electronically encrypted form. Data contained in the LHID2000 are randomly selected from one million subjects from the NHIRD and are made available for research purposes \[[@B13]\]. Data from the LHID2000 used in this study included patient identification numbers, gender and age, monthly salary, occupation type, diagnostic data, antiglaucoma drug codes, and surgery codes. Diseases are defined in accordance with A codes (A230) before 2000 and International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM365), after 2000.

The study received approval from the Ethics Committee of the Institutional Review Board of the Changhua Christian Hospital and was conducted in accordance with the tenants of the Declaration of Helsinki.

2.2. Study Sample {#sec2.2}
-----------------

This study group comprised all patients with glaucoma during the period 1997 to 2010. Topical glaucoma medications included PGAs, *β*-blockers, *α*-agonists, CAIs, cholinergic agonist, *β*-blockers/CAIs fixed combinations, *β*-blockers/*α*-agonists fixed combination, *β*-blockers/PGAs fixed combinations, and adrenergic agonists. Data on frequency of trabeculectomy were also collected.

2.3. Statistical Analyses {#sec2.3}
-------------------------

The annual expenditures for glaucoma patients were adjusted for inflation as of 2011. The trend test for expenditure was analyzed with linear regression weighted with the inverse of squares residual. The associations between increase and decline in medication costs were analyzed with Pearson correlation. The trend test for frequency of trabeculectomy was analyzed with the Chow test \[[@B14]\]. We also assessed the effect of demographic factors on glaucoma expenditure using a generalized estimating equation regression model (GEE). A *P* value \<0.05 was considered to indicate statistical significance; all tests were two-tailed. All statistical analyses were conducted using the statistical package SAS for Windows (Version 9.2).

3. Results {#sec3}
==========

The number of beneficiaries included in the LHID2000 sample declined from 916,626 persons in 1997 to 859,913 persons in 2010. The number of patients receiving antiglaucoma drugs increased from 3105 in 1997 to 7033 in 2010 ([Table 1](#tab1){ref-type="table"}).

3.1. Overall Costs {#sec3.1}
------------------

After adjusting for inflation, the total annual medical expenditures increased from \$0.21 million in 1997 to \$0.63 million in 2010 (slope = \$37,618/year, *P* \< 0.001) ([Table 1](#tab1){ref-type="table"}). The increase in total expenditures was remarkable in both genders, every age group, every income group, and every occupation group (*P* \< 0.05). Annual glaucoma medication expenditures for men were higher than those for women after 2000. The annual glaucoma medication expenditures were most prominent in the age group ≥65 years, followed by the age group 40--64 years and the age group \<40 years ([Figure 1](#fig1){ref-type="fig"}). The lowest income group spent more money on antiglaucoma medications than other income groups. The white-collar occupation group spent more money on medications than the other occupation groups.

3.2. Per Capita Expenditure Costs {#sec3.2}
---------------------------------

The mean medication expenditure per person increased from \$67.3 in 1997 to \$90 in 2010 after adjusting for inflation (slope = \$2.8/year, *P* \< 0.001) ([Table 1](#tab1){ref-type="table"}). The mean cost per capita increased year on year from 1997 to 2006 and then decreased gradually after 2007. The trend in mean medication expenditures per person was similar in each category (gender, age, income, and occupation group). Estimates from the GEE conducted to determine demographic variables associated with the increase in glaucoma medication expenditure indicate that patients ≥40 years incurred higher costs for medication than patients under the age of 40 years (*P* \< 0.001). In the same analysis, men incurred higher costs than women (*P* \< 0.05), populations with higher income incurred higher costs for medications than populations with lower income (*P* \< 0.05), glaucoma medication expenditures increased year on year (*P* \< 0.001), and blue-collar workers had lower expenditures than the other types of workers (*P* \< 0.001) ([Table 2](#tab2){ref-type="table"}).

3.3. The Changes of Expenditure between Different Glaucoma Medications {#sec3.3}
----------------------------------------------------------------------

The annual expenditures for most classes of glaucoma medications increased during the study period, except for *β*-blockers (slope = −\$10,152/year, *P* \< 0.001) and cholinergic agonists (slope = −\$432/year, *P* \< 0.001) ([Table 1](#tab1){ref-type="table"}). The decrease in expenditure for *β*-blockers was associated with the administration of PGAs (*P* = 0.002), and *α*-agonists (*P* \< 0.001). A significant increase in expenditures on PGAs (slope = \$23,779/year, *P* \< 0.001) was also noted. Medications containing PGAs accounted for 46% of the total glaucoma medication expenditure in 2010 ([Table 1](#tab1){ref-type="table"}) ([Figure 2](#fig2){ref-type="fig"}).

We also found a decreasing trend in per capita medication expenditures for *β*-blockers (slope = −\$0.5/year, *P* \< 0.001) and cholinergic agonists (slope = −\$0.5/year, *P* \< 0.001). However, the trends for other glaucoma medications were not significant ([Table 1](#tab1){ref-type="table"}).

3.4. The Change of Trabeculectomy Number during the Study Period {#sec3.4}
----------------------------------------------------------------

The numbers of trabeculectomies performed during the study period are shown in [Table 1](#tab1){ref-type="table"}. During the period 1997--2010, we found that the frequency of trabeculectomy had two break points, one in the year 1999 and the other in the year 2000 based on the Chow test \[[@B14]\].

4. Discussion {#sec4}
=============

During the study period, the total expenditures for glaucoma medications significantly increased by 3.03-fold because of an increase in patient numbers and an increase in mean medication expenditures per person. The increase in patient numbers may be related to the early diagnosis due to advanced diagnostic modalities (e.g., optical coherence tomography), more accurate diagnosis, overdiagnosis, aging population, or good medical accessibility in Taiwan \[[@B10], [@B11], [@B15]\]. The increase in mean medication expenditure per person may be associated with the administration of PGAs and more aggressive glaucoma treatment \[[@B5]\]. The rising cost of glaucoma drugs after PGAs launching also occurred in Ireland, Scotland, Australia, Denmark, and France \[[@B16]\].

As seen in [Table 2](#tab2){ref-type="table"}, mean glaucoma medication expenditures increased markedly after the NHI system began covering treatment with PGAs in 2000. The reduction of expenditure per capita after 2007 and the mean medication cost in Taiwan was much lower than in Denmark and the United States \[[@B8], [@B9]\] reflecting the success of bargaining medication cost and prescription policy (beta-blocker should be first-line drug) by Taiwan NHI. However, the increasing total medication expenditure imaged that the cost down policy could not offset the growing medical demand.

In this study, expenditures for glaucoma medications were significantly higher for men than for women, whereas in the USA the opposite is true \[[@B8]\]. The possible reasons are differences in knowledge of health issues between genders in different societies and the higher prevalence of ACG in Taiwan \[[@B2], [@B17]\]. Women are at higher risk of ACG \[[@B18]\] that can be treated with laser iridotomy or cataract surgery rather than glaucoma medications. Cataract surgery is readily available in Taiwan and the procedure reduces the likelihood of developing the disease \[[@B13], [@B19]\].

It is not surprising that glaucoma medical expenditures were highest among patients ≥65 years because aging is one of the risk factors for developing glaucoma. In this study, the glaucoma medical expenditures for the age group over 65 years significantly increased and accounted for more than half the amount of medical expenditures; a reflection of Taiwan\'s aging population has great financial burden in glaucoma care. Furthermore, we also found that expenditures for glaucoma medications increased significantly for patients in the age group \<40 years, possibly because of advanced diagnostic tools, more aggressive glaucoma treatment, and the high prevalence of myopia among younger people in Taiwan \[[@B5], [@B15], [@B20]\].

The study results show that blue-collar workers have lower glaucoma medical expenditures, while higher income families incur higher glaucoma medical expenditures, indicating inequality in health care services under universal health coverage in Taiwan. Such inequality may be the result of differences in general knowledge of health care, out-of-pocket payment policy, and other socioeconomic disparities \[[@B10], [@B21], [@B22]\].

The total expenditure for *β*-blockers decreased because of the reduction in cost by the bureau of NHI and the decrease in usage of *β*-blockers, mainly due to the increased availability of PGAs and *α*-agonists. However, considering the drug price, the Taiwan NHI stipulates that *β*-blockers are first-line medications and PGAs, CAIs, and fixed combinations are second-line medications. Therefore, *β*-blockers still have a considerable market share in Taiwan, despite the fact that PGAs are more effective, are associated with fewer adverse effects, require only once-a-day dosing, and are associated with greater patient compliance \[[@B23]\]. The medical expenditures in the USA have also undergone similar changes relative to insurance coverage \[[@B8]\].

Cholinergic agonists are mainly used for ACG. Even though most people in Taiwan are Chinese in origin and have a higher prevalence of ACG \[[@B2], [@B17]\], there has been a decreasing trend in the application of cholinergic agonists, which may be offset by the increased availability of other drugs like PGAs and the increase in frequency of cataract surgery in Taiwan \[[@B13], [@B23]\]. The trend in increasing expenditures for fixed combinations of medications during the period of study can be attributed to patients\' preference, because the fixed combinations improve medical adherence and reduce eye discomfort \[[@B6]\].

Trabeculectomy is the most common glaucoma surgery in Taiwan. Our study reveals that the number of trabeculectomies decreased significantly in 1999 and 2000, at the time when PGAs were launched and the Taiwan NHI began to reimburse expenses for PGAs. A similar situation of decreasing the number of trabeculectomies after PGAs listing was also reported in Scotland, France, and Australia \[[@B16]\]. Trabeculectomy is more effective in reducing IOP and lowering diurnal tension than PGAs \[[@B24]\]. However, the side effects of trabeculectomy are greater than those associated with PGAs. According to Cutler and McClellan \[[@B25]\], technological change affects treatment in two ways---treatment substitution and treatment expansion or both. Treatment substitution implies a new technology in place of an old one. Treatment expansion takes place when treatments become safer and easier, and patients pay more attention to their conditions when therapy is more effective or less side effective. Based on the results of this study, we presume that PGAs may have the effect of treatment expansion for trabeculectomy under universal health coverage.

There are several limitations to this study. First of all, the study ignored patient adherence and disease severity. Poor patient adherence may reduce medication expenditures at first but eventually will increase medical and surgical expenditures due to symptom complications. Realistically, severities of glaucoma are related to medical expenditures. Secondarily, insured salary is not necessarily truly representative of patients\' socioeconomic status. Most people are employees and pay the insurance fee according to their salary. However, the health insurance fee is lower for those living on their investments. We cannot definitely determine the interaction between socioeconomic status and glaucoma medical expenditures. Thirdly, we did not characterize which types of glaucoma and which education levels contributed to medical expenditures.

5. Conclusions {#sec5}
==============

This nationwide population-based study demonstrated an increasing trend in glaucoma medical expenditures from 1997 to 2010 in Taiwan. The main factors contributing to these trends include administration of brand-name drug products such as PGAs, the increasing glaucoma population, good medical accessibility, and possibly more aggressive treatment. PGAs may have the effect of treatment expansion for trabeculectomy. Expenditures were highest among men, patients over 40 years of age, and patients with higher incomes and were lowest among blue-collar workers. The inequality of health care in different socioeconomic disparities may still exist in Taiwan.
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###### 

Total and mean glaucoma medication expenditure (USD, adjusted for inflation to the 2011 Consumer Price Index of Taiwan), LHID2000.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                               Total glaucoma medication cost (mean cost per person)                                                                                                                                               
  ---------------------------- ------------------------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  Total expenditure            208,858                                                 212849    249,959   291,523   333,204   397,456   414,489   495,927   552,024   591,417   589,885   614,044   611,331   633,151   37,618    \<0.001

  (67.3)                       (60.8)                                                  (68.3)    (79.0)    (87.1)    (96.5)    (93.8)    (98.2)    (102.0)   (105.0)   (99.4)    (97.5)    (90.6)    (90.0)    2.8       \<0.001   

  Gender                                                                                                                                                                                                                            

   Male                        100,245                                                 104,485   123,542   147,789   167,646   202,446   214,111   258,024   285,850   307,655   312,891   325,681   325,892   337,195   20,567    \<0.001

  (68.1)                       (62.7)                                                  (70.9)    (84.1)    (90.6)    (99.9)    (100.1)   (105.5)   (108.3)   (111.0)   (109.1)   (105.0)   (97.9)    (95.7)    3.5       \<0.001   

   Female                      108,613                                                 108,364   126,417   143,734   165,558   195,010   200,379   237,903   266,174   283,762   276,994   288,364   285,439   295,956   17,013    \<0.001

  (66.6)                       (59.0)                                                  (65.9)    (74.4)    (83.9)    (93.3)    (87.8)    (91.4)    (96.1)    (99.1)    (90.4)    (90.2)    (83.6)    (84.3)    2.2       0.004     

  Age                                                                                                                                                                                                                               

   \<40                        21,558                                                  22,522    23,960    28,747    37,071    47,405    46,926    55,595    60,910    63,110    61,386    62,593    58,693    58,665    3,965     \<0.001

  (46.3)                       (40.1)                                                  (42.2)    (49.5)    (66.8)    (74.5)    (71.8)    (71.4)    (74.1)    (80.2)    (77.6)    (74.8)    (67.9)    (67.5)    2.6       0.001     

   40--64                      81,136                                                  81,205    93,961    113,495   126,037   142,456   147,223   174,562   194,788   208,877   206,852   215,594   221,214   228,075   12,963    \<0.001

  (64.7)                       (59.6)                                                  (65.8)    (78.1)    (83.6)    (90.8)    (85.0)    (89.2)    (93.5)    (95.9)    (90.5)    (89.5)    (83.9)    (84.3)    2.0       0.003     

   ≥65                         106,165                                                 109,121   132,038   149,281   170,096   207,595   220,340   265,770   296,327   319,430   321,647   335,858   331,424   346,410   20,982    \<0.001

  (76.7)                       (69.1)                                                  (79.3)    (90.2)    (96.6)    (108.5)   (108.4)   (114.9)   (118.3)   (119.8)   (112.6)   (110.0)   (102.2)   (100.2)   3.3       \<0.001   

  Monthly income                                                                                                                                                                                                                    

   ≤610                        121,072                                                 117,866   135,830   158,382   183,680   216,500   225,130   263,846   287,919   300,211   291,968   299,156   288,696   292,996   17,296    \<0.001

  (73.7)                       (65.6)                                                  (71.6)    (84.7)    (94.1)    (102.7)   (100.1)   (103.8)   (108.0)   (109.4)   (102.9)   (100.6)   (92.3)    (92.2)    2.5       0.005     

   611--1220                   71,896                                                  77,079    92,189    102,596   114,674   137,747   142,387   172,602   194,157   211,463   214,992   228,099   232,210   242,717   14,528    \<0.001

  (58.9)                       (55.2)                                                  (64.5)    (71.0)    (76.3)    (85.2)    (82.3)    (88.5)    (90.5)    (95.1)    (91.0)    (91.0)    (85.1)    (84.3)    2.9       \<0.001   

   \>1220                      15,889                                                  17,904    21,940    30,546    34,850    43,209    46,972    59,480    69,948    79,743    82,926    86,789    90,426    97,439    6,867     \<0.001

  (65.7)                       (57.9)                                                  (65.3)    (82.1)    (94.2)    (109.7)   (107.0)   (106.8)   (117.0)   (119.9)   (113.1)   (106.2)   (102.1)   (99.7)    4.0       0.001     

  Occupation                                                                                                                                                                                                                        

   White-collar                90,794                                                  92,736    108,883   127,199   147,618   172,884   176,803   215,931   248,346   268,507   273,476   287,715   289,024   303,343   18,495    \<0.001

  (69.5)                       (62.4)                                                  (69.0)    (80.2)    (88.3)    (95.9)    (90.7)    (93.5)    (100.2)   (103.6)   (99.8)    (96.5)    (90.3)    (90.1)    2.5       0.001     

   Blue-collar                 67,431                                                  69,645    81,244    91,903    102,067   123,503   128,240   153,700   172,262   188,362   188,384   196,023   195,304   205,480   11,985    \<0.001

  (58.7)                       (53.2)                                                  (60.8)    (68.1)    (74.3)    (83.4)    (81.6)    (86.7)    (88.9)    (93.0)    (88.1)    (87.2)    (81.3)    (82.1)    2.7       \<0.001   

   Other                       50,633                                                  50,468    59,832    72,422    83,519    101,069   109,446   126,296   131,416   134,548   128,025   130,307   127,004   124,328   7,902     \<0.001

  (78.0)                       (71.4)                                                  (79.9)    (96.2)    (107.4)   (120.9)   (121.9)   (130.6)   (132.2)   (132.4)   (121.6)   (122.1)   (111.1)   (107.0)   4.0       0.002     

  Glaucoma medication^a^                                                                                                                                                                                                            

   PGAs                                                                                                    19,283    72,406    120,877   141,191   185,021   221,495   241,386   248,635   259,079   242,699   250,057   23,779    \<0.001

                                                                                                 (80.0)    (138.2)   (150.2)   (127.0)   (127.0)   (132.8)   (135.2)   (130.9)   (129.2)   (116.5)   (112.6)   0.4       0.787     

    *β*-blockers               200,229                                                 204,690   219,951   217,671   199,730   198,074   179,209   176,870   166,256   155,935   127,751   123,041   111,916   95,682    −10,152   \<0.001

  (67.3)                       (60.4)                                                  (62.1)    (61.4)    (57.1)    (56.1)    (50.3)    (46.3)    (43.9)    (41.5)    (34.5)    (32.2)    (28.2)    (24.3)    −0.5      \<0.001   

    *α*-agonists                                                                                           180       9,720     26,053    33,311    50,288    58,937    66,428    71,139    74,891    80,729    90,018    8,697     \<0.001

                                                                                                 (18.0)    (37.4)    (52.6)    (54.3)    (54.8)    (54.5)    (55.2)    (52.2)    (50.5)    (48.0)    (48.4)    1.5       0.194     

   CAIs                                                                                          21,002    46,907    45,410    46,897    53,271    61,980    57,895    53,574    52,206    57,326    52,120    53,699    648       0.303

                                                                                       (72.2)    (92.9)    (83.0)    (83.0)    (84.3)    (91.8)    (90.0)    (85.4)    (81.1)    (84.9)    (75.0)    (70.9)    −1.5      0.060     

   Cholinergic\                8,629                                                   8,159     9,005     7,483     5,939     5,554     4,530     4,863     4,978     4,751     3,747     3,331     3,138     3,166     −432      \<0.001
    agonist                                                                                                                                                                                                                        

  (10.9)                       (9.5)                                                   (11.5)    (10.5)    (9.8)     (9.4)     (8.0)     (8.2)     (8.4)     (8.1)     (6.9)     (6.3)     (5.9)     (5.9)     −0.5      \<0.001   

    *β*-blockers/ \                                                                                                                      2,951     14,553    29,437    47,992    60,413    66,376    72,166    73,586    11,526    \<0.001
    CAIs                                                                                                                                                                                                                           

                                                                                                                               (57.9)    (77.8)    (87.3)    (93.2)    (99.2)    (93.1)    (95.7)    (90.4)    3.0       0.072     

    *β*-blockers/\                                                                                                                                                     34        1,134     3,373     12,115    24,760    5,750     0.028
     *α*-agonists                                                                                                                                                                                                                  

                                                                                                                                                             (17.1)    (51.5)    (54.4)    (64.8)    (79.9)    12.6      0.076     

    *β*-blockers/\                                                                                                                       26        2,351     13,026    21,316    24,860    26,603    36,433    42,184    8,042     \<0.001
    PGAs                                                                                                                                                                                                                           

                                                                                                                               (25.8)    (58.8)    (105.9)   (134.9)   (146.2)   (116.2)   (121.4)   (114.9)   9.8       0.079     

  Number of trabeculectomies   124                                                     126       100       69        73        65        64        66        63        70        75        61        70        68                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PGAs, prostaglandin analogues; CAIs, carbonic anhydrase inhibitors; LHID2000, National Longitudinal Health Insurance Database 2000.

*n* ^*∗*^, number of patients under glaucoma medication.

^a^Adrenergic agonists not shown because of small sample sizes.

###### 

The results of generalized estimating equations regression model (USD/year).

                                             Estimate   SE    *P* value
  ------------------------------------------ ---------- ----- -----------
  Intercept                                  33.4       1.5   \<0.001
  Age, year (versus \<40)                                      
   40--64                                    10.4       1.4   *\<*0.001
   ≥65                                       18.5       1.5   \<0.001
  Gender (versus female)                     2.2        1.1   0.041
  Income, USD (versus ≤610)                                    
   611--1220                                 −3.2       1.3   0.015
   \>1220                                    6.7        2.0   \<0.001
  Occupation (versus white-collar workers)                     
   Blue-collar workers                       −6.7       1.3   \<0.001
   Other types of workers                    6.8        1.6   \<0.001
  Year                                       1.0        0.1   \<0.001
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